News
|
Markets
|
watchlist
|
Menu
MARK SCHOENEBAUM
Related Articles
U.S. Stocks Rise as Bullard Says Stimulus Should Continue
3 days ago
Bristol-Myers Drug Cocktail Stymies Melanoma Tumors
8 days ago
Lilly Stops Trial of Lymphoma Drug Due to Ineffectiveness
14 days ago
Gilead Misses Analysts’ Estimates on Sales of HIV Drugs
1 months ago
Gilead’s Hepatitis C Treatment Clears Virus in Eight Weeks
1 months ago
Actavis Seen Selling for Higher Valuation: Real M&A
1 months ago
Merck Cuts Profit Forecast as Buyback Boosted $15 Billion
1 months ago
Pfizer Lowers 2013 Forecast After Sales Miss Estimates
1 months ago
Biogen MS Pill’s Early Sales May Help It Beat Estimates
1 months ago
Pfizer’s Arthritis Drug Rejected by European Regulators
1 months ago
Show More News
%7Cutmccn%3D(direct)%7Cutmcmd%3D(none);&utmn=512481795&utmp=%2Ftopics%2Fmark-schoenebaum%2F&utmhn=10.248.179.17&utmac=UA-11413116-12&utmhid=263174606)